publication, as of 2026-11-07
https://www.esmoopen.com/article/S2059-7029(26)01903-4/fulltext
By March 2025, among 158 GIST pts in the 2nd line to >= 4th line therapies, ORR was 28.5%, DoR 11.5 months, DCR 77.8% and PFS 9.2 months. Significantly, the pts in third-line therapy showed ORR 46.7%, DoR 12 months, DCR 90% and PFS 13.7 months. ... NB003 is administrated at 15 mg BID
ESMO Open 157TiP (2026), GISTAR-1 design (NCT07379047)
registry, as of 2026-11-07
https://clinicaltrials.gov/study/NCT04936178
A Multicenter Phase 1, Open-Label Study of NB003 to Assess Safety, Tolerability, Pharmacokinetics and Efficacy in Patients With Advanced Malignancies
ClinicalTrials.gov API v2 record, retrieved 2026-11-07
registry, as of 2026-11-07
https://clinicaltrials.gov/study/NCT07379047
A Multicenter, Open-label Clinical Study to Evaluate the Efficacy and Safety of NB003 in Patients With Advanced Gastrointestinal Stromal Tumors (GIST)
ClinicalTrials.gov API v2 record, retrieved 2026-11-07
Registry NCT04936178
Phase Phase 1
Status Completed
Enrollment 258
Start 2021-08-06
Primary completion 2025-08-01
Study completion 2025-08-01
NB003, 2L to 4L or later
Dose not stated in source
Population GIST 2L to 4L or later (n = 158)
Estimand Single arm
objective response rate: 28.5%, data as of March 2025
median progression-free survival: 9.2 months, data as of March 2025
NB003, 3L subgroup
Dose not stated in source
Population GIST 3L (n not stated in source)
Estimand Single arm
objective response rate: 46.7%, data as of March 2025
median progression-free survival: 13.7 months, data as of March 2025
Registry NCT07379047
Phase Phase 2/3
Status Recruiting
Enrollment 255
Start 2026-05-11
Primary completion 2028-08-01
Study completion 2028-09-01
Catalyst Primary completion. 08.01.2028. ClinicalTrials.gov primary completion date. This is a registry date, not a company readout.
NB003 15 mg BID (Part 1)
Dose 15 mg
Regimen twice daily
Comparator regorafenib 160 mg
Population 3L GIST after imatinib and sunitinib
Estimand ITT
Regorafenib 160 mg
Dose 160 mg
Regimen once daily
Population 3L GIST
Estimand ITT